Member Info for jam2morrow

@Malafuster....the price movements on AIM are much exaggerated compared to the volumes sold. We saw yesterday that this sp was prepared to jump a good 15% on that RNS, but sells of perhaps 0.2 or 0.3 % of issued shares have been enough to take all momentum out of that rise (sellers would have needed more than this to dampen down the late December RNS, but not unfeasible amount). If sellers were wanting to keep a lid on sp then yesterdays RNS was the last piece of good news that was due.....apart from order book news, of course.
Its not in Amati's interest to keep sp down......possibly u could make a case for Bracco but I don't think so.
A lot depends on POLX themselves, they've been through a tough process with the FDA and there will be a lot of work to do to roll this out, if they want to go it alone; probably another fundraise at some stage as well. Do they have the will to keep on ? I suspect strategic background selling to keep the pressure on POLX

@Dan.... I was convinced that another share I was in was being sold into to keep price down; it wasn't long before an offer was made for the company and the offeror quoted a moving average of the share price over the last 3 months as the basis for their offer price. Of course, impossible to prove, but the cynic in me is still convinced that the price was kept artificially low.
Its interesting, the price/trade surge action here in the last 5 minutes, I kind of understand people buying in because of the RNS, but that doesn't really make complete sense given the way the orange book works. What I don't understand is people getting the RNS 'ping' and thinking ''right thats the sell signal''.
Any rise is quickly sold into and I think same tomorrow, let's see

@SLF72, re Bracco....by my reckoning they have invested cica £4.7 M.....they bought the majority, 12M at 18p but then another 4.2M at the last placing, at 60p.
I would be interested to know when and what price Amati bought in, if anyone knows ? I assumed they got hold of the AMP shares but I could be way off there, and i can't see an RNS
S##t show today, and probably will go lower. Its difficult to put a valuation on it. They need sales obviously, but I think if they do get sales they will use it to support another fund raise.
My preferred outcome at present is takeover, but it would be in buyers interest to let this fall play out before any offer. 50/60/70% over market value is normal offer level !

large sell at 10.30, and there will be continued selling with a perceived empty order book. Year lows 39p ......looks like will go below that, but how far ?

'seller cleared'......makes me smile because the phrase is seen so often across these chat-boards. Like consciously or un- consciously the poster is trying to convince themslves, or the rest of us, that one bad person is responsible for the relentless decrease in the value of our investment.
Lots of people bought in to the clearance RNS (a few very canny people sold out) and now they are gradually selling out because it seems the company has no sales lined up. How long POLX can go on with the news blackout is the question. Does anybody know the timescales for the hatch waxman process ? Is that tied in with the FDA as well or a seperate organisation ?

The silence is strange; possibly they have no sales in the pipeline and are choosing not to advertise the fact; possibly buyout talks (if it is, I think posters on here will be surprised at how low prospective offers will be); possibly waiting for hatch waxman update ?
There is some level of activity here tho'......that 100k shares (looks like) bought at 12.20ish, is not just punt money, you would hope!

fair points @tomorrow. Also I agree could be around 40p if no news in next few weeks. Seems a bit weird that they haven't arranged an interview with proactive(already have done a few) to advertise the product, talk about the way forward, hatch waxman etc.
I would not be as sure as you are about prospective takeover bids; IMO industry will be well aware of the product and its capabilities, even if many hospitals are not. GE health care are massive and sold the patents to POLX to get them started; Bracco not so big, but obviously aware. Why wait until sales and sp start climbing if buyout was on the radar ?
I'm 20% down at these levels, wish they'd do more on the comms/PR front, but still comfortable holding and maybe adding if it drifts more

It shows how much the market has changed in 2 years @Rex.
Without sales, sp is only going one way; and really, FDA approval has given the sp sweet F...d...A.
The problem, as I see it, is that orders of the device over this time span have been to research hospitals and have been bought with grant/govt money. For the company to be successful there has to be demand from hospitals that are regularly doing pulmonary MRI patient scans. How many lung MRI scans are done daily in US ?
I believe in the equipment, but if there was a pent up desire to buy it, then sp wouldn't be where it is.
I agree with the correspondent u quote, that it will be a buyout target, but in Feb '21 he is saying between £500M and 1B. I think £200M would be a very genorous offer in present financial climate. Are u watching GE health care, Bracco ?

Same @ISA......we haven't had an RNS so i wonder whats changed. Not a lot of use to me this tax year as i don't have any taxable gains that i can discount against MTFB. Does anybody know if we can use this 'deemed worthless' category in the next tax year/ future tax years ?

@ napalm, they don't, not for certain. Depends which way u want to spin it, 2 buys, 2 sells ?.... I'll go for 1 buy, 1 sell pre-arranged between 2 parties off book. Someone wants their money out, someone prepared to buy in....

we need some sales news otherwise we're only going one way. On the takeover thread, 50% over market price is a normal offer level and at the moment thats not even 75p! The market isn't pricing in many sales at the mo'.......I'm holding now out of hope than expectation.....come on POLX sales RNS please !

uncrossing trade at 51p...... we've fallen off sharply since the 28th spike......still a bit more interest than at pre-approval tho'.
A takeover by a bigger fish who can ride out this bear market has to be a possibility, especially at these levels

a new VOX discussion with Paul Hill and Justin Waite, some discussion of Polarean about half way. Shame its not with the Amati guy because he might give a bit more insight. Doesn't tell us anything we don't know really but i expect holders will be interested.
https://www.youtube.com/watch?v=wv0zdXmm6qA

copied from polarean website :
'' The Board places great importance on the need for effective communication with investors and the media. To ensure that all existing and future stakeholders are able to track our progress and obtain updates as soon as available, we would encourage registration to our alert service.''
Some communication would be nice, alert service or not. We have been working up to that approval for ages and then just to say......ok its approved is a bit underwhelming.
Does anybody know if the machines being used on trial/experimental basis have been purchased outright already, or will they need to be bought to be retained ?
I'd like to hear the Amati fund managers take, interview please VOX !
If the tech is the cat's pyjamas then must be a takeover target at these prices I'd have thought.......80p offer ?

the 2 takeovers that i've been a holder of, the offer was below 50% increase on market price......and they got them. That translates to an offer here of circa 80p. The FDA delay has been a big dampener but it should have given the company ample time to assess sales viabilities in US. The approval RNS gave us no hints, so there's gonna be speculation

Share price is disappointing because we could have bought at these levels without approval. The mistake i made was assuming that approval would fix us in 60's/ 70's and then would depend on sales progress which way we went. Looks like the market was ahead of me and approval has been pretty much priced in since the 3 mth extension.
No TR1's since approval so the big holders staying put (possibly they've adjusted slightly?). I'll hold as well and hope for some positive newsflow. Any new sales have been RNS'd in the past, so hopefully something soon. Will be interesting to hear what the Amati guy has to say if VOX get an interview with him

'drink radiation to image lungs'.......Maestro has maybe exaggerated the danger to strengthen the point....but it does happen. A tracer or radionuclide would be ingested or injected so that images of the target organ would be enhanced on scan, you will have to research online because i don't know enough about it. What I 'understand' is that this procedure, in a pulmonary context, is used for lung perfusion scans. Interestingly, in the approval RNS, it states :
'' XENOVIEW has not been evaluated for use with lung perfusion imaging.''
I expect POLX will want the product to be used for perfusion imaging as well, in time.
The price is where it is because the market is uncertain on revenues in the next 6mths. Hindsight is easy, but approval was probably pretty much priced in to the early december market.
Budgets are tight, but there's a lot of wealthy people in America. Will be interesting to see how this plays out, and if any of the big Co's start sniffing around for a bargain

wonder if this will be on Justin Urquhart Stewarts share tips pick for next year. I mean if he tipped it at 28p last year then he's got to tip it this year at 10p, right ?
Keep smiling LTH's, happy new year.
Last years caveat - only for the brave !
This years caveat - only for the very brave

we had 38.2M US June 21 ......we had 22.7M US June 22 so on that burn rate we maybe have 15M US now. They will need to get sales going quickly or else raise/other finance . Last time they raised with equity , the placing was at 60p, not much of a discount as i recall

hatch waxman just sets out the period of exclusivity for newly approved drugs - 5 years i think. My understanding is that it would apply to all. Don't think its so much of an issue here because this is a medical device, not a chemical compound that could be replicated cheaply . All my understanding only...happy to be corrected !
I do think manufacturers of MRI machines will be watching this closely